Slides
Page 1
June 23, 2025 MariTide Update
Page 2
2 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon’s business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. The scientific information discussed in this presentation related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Further, any scientific information discussed in this presentation relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this presentation, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.
Page 3
3 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. MariTide: A Unique, Differentiated and Competitive Profile • First obesity treatment with monthly or less frequent dosing • Strong efficacy with up to ~20% weight loss without a plateau at 52 weeks • Meaningful improvements in cardiometabolic parameters including HbA1c, systolic blood pressure, and high-sensitivity C-reactive protein • Tolerability consistent with the GLP -1 class for gastrointestinal adverse events and overall • Dose escalation significantly improves tolerability without compromising weight loss efficacy • Phase 3 MARITIME chronic weight management studies underway with further optimized three- step dose escalation for additional tolerability improvements • MariTide’s simple and convenient dosing can potentially improve adherence and long -term weight control, providing the opportunity to optimize health outcomes for people living with obesity and obesity related conditions including Type 2 diabetes HbA1c = hemoglobin A1c; GLP-1 = glucagon-like peptide 1.
Page 4
4 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. MariTide Update Today’s Topics 52-Week Data from Part 1 of the Phase 2 study1 Phase 3 Chronic Weight Management Study Design3 Phase 1 Pharmacokinetic Low Dose Initiation Study2 MariTide Data Generation4
Page 5
5 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. MariTide: First Monthly or Less Frequent Treatment for Obesity and Type 2 Diabetes Monoclonal (anti-GIPR) antibody backbone with long half-life enables monthly or less frequent dosing Two GLP-1R analog peptides positioned for optimal efficacy GIPR = glucose-dependent insulinotropic polypeptide receptor; GLP-1R = glucagon-like peptide 1 receptor. Véniant MM, Lu SC, Atangan L, et al. Nat Metab. 2024;6(2):290-303. MariTide’s simple and convenient dosing can potentially improve adherence and long-term weight control, providing the opportunity to optimize health outcomes for people living with obesity
Page 6
6 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. Overview of MariTide Phase 2 Study (Part 1) • 52 week duration • 2 cohorts 1. Adults living with obesity or overweight WITHOUT Type 2 diabetes 2. Adults living with obesity or overweight WITH Type 2 diabetes • 592 adult patients • 11 arms, including 2 rapid dose escalation arms which both initiated with a 70 mg dose • Monthly or less frequent dose schedules OBESITY or Overweight WITH Type 2 Diabetes (n=127) 0 4 8 12 16 5220 24 28 32 36 40 44 48 WEEKS Placebo 420 mg monthly 280 mg monthly 140 mg monthly 0 2 4 8 12 16 5220 24 28 32 36 40 44 48 WEEKS Placebo 420 mg every other month 280 mg monthly 140 mg monthly 420 mg monthly DOSE ESCALATION ARMS 70 mg 70 mg 70 mg 140 mg 280 mg 4-week dose escalation then 420 mg monthly 12-week dose escalation then 420 mg monthly Obesity or Overweight WITHOUT Type 2 Diabetes (n=465) mg = milligram.
Page 7
7 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. MariTide Demonstrated Consistent Weight Loss Across All Target Dose Arms in Adults With Obesity WITHOUT Type 2 Diabetes These and all subsequent efficacy data reported are based on a standard analytical measure commonly used for obesity medicine s, the efficacy estimand. Substantial and statistically significant weight loss in all treatment arms Percent change in body weight Weeks Placebo140 mg Q4W (no dose escalation) 280 mg Q4W (no dose escalation) 420 mg Q4W (4W 70 mg one-step dose escalation) 420 mg Q4W (12W 70 mg one-step dose escalation) 420 mg Q8W (no dose escalation) 420 mg Q4W (no dose escalation) • MariTide demonstrated up to ~ 20% average weight loss without a plateau at 52 weeks • Confirmed efficacy of monthly dosing with potential for less frequent dosing • No weight loss plateau in any arm at 52 weeks • Up to ~98% of patients lost ≥5% of their body weight Overall mean baseline weight = 107.4 kg5 0 -5 -10 -15 -20 -25 0 4 8 12 16 20 24 28 32 36 40 44 48 52 -2.6 -16.3 -16.7 -17.7 -18.9 -19.9 -19.9 kg = kilograms; mg = milligrams; Q4W = every 4 weeks; Q8W = every eight weeks.
Page 8
8 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. -18.9 -17.7 -16.7 -19.9 -2.6 -25 -20 -15 -10 -5 0 5 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 Percent change in body weight Weeks Overall mean baseline weight = 107.4 kg Dose Escalation and Every Other Month Dosing of MariTide Demonstrated Efficacy Comparable to 420 mg Monthly Dosing • Dose escalation resulted in similar magnitude of weight loss compared to no dose escalation • Every other month dosing resulted in significant weight loss, reinforcing potential for less frequent dosing These and all subsequent efficacy data reported are based on a standard analytical measure commonly used for obesity medicine s, the efficacy estimand. Substantial and statistically significant weight loss in all treatment arms 420 mg Q4W (4W 70 mg one-step dose escalation) Placebo 420 mg Q4W (12W 70 mg one-step dose escalation)420 mg Q8W (no dose escalation) 420 mg Q4W (no dose escalation) kg = kilogram; mg = milligram; Q4W = every 4 weeks; Q8W = every eight weeks.
Page 9
9 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. • Substantial and statistically significant weight loss in all treatment arms • Confirmed efficacy of monthly dosing • No weight loss plateau in any arm, indicating the potential for further weight loss beyond 52 weeks • Up to ~99% of patients lost ≥ 5% of their body weight -1.4 -12.3 -12.1 -17.0 -20 -18 -16 -14 -12 -10 -8 -6 -4 -2 0 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Weeks Percent Change in Body Weight estimated mean (95% CI) MariTide Demonstrated an Impressive Up to ~17% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in Adults With Obesity WITH Type 2 Diabetes These and all subsequent efficacy data reported are based on a standard analytical measure commonly used for obesity medicine s, the efficacy estimand. Placebo 420 mg Q4W (no dose escalation)140 mg Q4W (no dose escalation) 280 mg Q4W (no dose escalation) mg = milligrams; Q4W = every 4 weeks; CI = confidence interval.
Page 10
10 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. MariTide Demonstrated Significant and Clinically Meaningful Improvements in Cardiometabolic Parameters in Adults With Obesity WITH Type 2 Diabetes SELECT CARDIOMETABOLIC RISK FACTORS CHANGE FROM BASELINE TO W52 FOR PLACEBO CHANGE FROM BASELINE TO W52 FOR MARITIDE 420 mg MONTHLY HbA1c +0.1% - 2.2%* Glucose +22 mg/dL - 58 mg/dL* Systolic blood pressure -2 mmHg - 11 mmHg* Triglycerides +21%* - 28%* hs-CRP -25% - 72%* Overall mean baseline HbA1c = 7.9% Weeks Change in hemoglobin A1c (%) *statistically significant from baseline. These and all subsequent efficacy data reported are based on a standard analytical measure commonly used for obesity medicine s, the efficacy estimand. LDL-C was similar between placebo and MariTide 420 mg. Placebo 420 mg Q4W (no dose escalation)140 mg Q4W (no dose escalation) 280 mg Q4W (no dose escalation) -1.9 -2.0 -2.2 0.1 -2.5 -2 -1.5 -1 -0.5 0 0.5 1 0 4 8 12 16 20 24 28 32 36 40 44 48 52 dl = deciliter; HbA1c = hemoglobin A1c; hsCRP = high-sensitivity C-reactive protein; LDL-C = low-density lipoprotein cholesterol; mg = milligrams; mmHg = millimeters of mercury; Q4W = every 4 weeks; W52 = week 52.
Page 11
11 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. MariTide Demonstrated Significant and Clinically Meaningful Improvements in Cardiometabolic Parameters in Adults With Obesity WITHOUT Type 2 Diabetes SELECT CARDIOMETABOLIC RISK FACTORS CHANGE FROM BASELINE TO W52 FOR PLACEBO CHANGE FROM BASELINE TO W52 FOR POOLED 420 MARITIDE DOSE ARMS Systolic blood pressure - 3 mmHg - 11 mmHg* LDL-C +1% - 5%* Triglycerides +1% - 19%* hs-CRP +1% - 53%* Overall mean baseline HbA1c = 5.5% Change in hemoglobin A1c (%) *statistically significant from baseline. These and all subsequent efficacy data reported are based on a standard analytical measure commonly used for obesity medicine s, the efficacy estimand. Weeks Placebo140 mg Q4W (no dose escalation) 280 mg Q4W (no dose escalation) 420 mg Q4W (4W 70 mg one-step dose escalation) 420 mg Q4W (12W 70 mg one-step dose escalation) 420 mg Q8W (no dose escalation) 420 mg Q4W (no dose escalation) Across all arms, between 70% and 96% of patients with prediabetes (HbA1c 5.7-6.4%) at baseline achieved an HbA1c <5.7% -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 0.0 -1 -0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 HbA1c = hemoglobin A1c; hs-CRP = high-sensitivity C-reactive protein; LDL-C = low-density lipoprotein cholesterol; mmHg = millimeters of mercury; Q4W = every 4 weeks; Q8W = every 8 weeks; W52 = week 52.
Page 12
12 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. Findings From Multiple Studies Provide the Insights to Optimize MariTide’s Tolerability Profile in Phase 3 • Overall safety consistent with GLP-1 class • Efficacy is durable, while gastrointestinal adverse events are short lived and predominantly associated with initial doses of MariTide • MariTide is well tolerated at target dose • Dose escalation significantly improves tolerability during initial dosing ◦ With one-step dose escalation in the Phase 2 study, vomiting incidence was reduced and discontinuation rate due to GI AEs was low (8%) ◦ Two-step dose escalation in the Phase 1 Low Dose Initiation study further reduced vomiting incidence with no discontinuation due to GI AEs AE = adverse event; GI = gastrointestinal; GLP-1 = glucagon-like peptide 1.
Page 13
13 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. In Part 1 of the Phase 2 Study, MariTide was Well Tolerated at Target Doses No-Step (No Dose Escalation) 100 90 80 70 60 50 40 30 20 10 0 Vomiting Incidence rate (%)1 2 4 8 12 16 20 24 28 32 36 40 44 48 Time since first dose of IP (weeks) 100 90 80 70 60 50 40 30 20 10 0 Vomiting Incidence rate (%)1 2 4 8 12 16 20 24 28 32 36 40 44 48 Time since first dose of IP (weeks) 420 mg Q4W 420 mg Q8W 52 52 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg Mild Moderate Severe The incidence graph captures the proportion of subjects who have an AE start within the period captured. For example, during week 1, this is the proportion of subjects with a new AE reported during days 1-7. IP = investigational product; mg = milligrams; Q4W = every 4 weeks; Q8W = every 8 weeks; AE = adverse event.
Page 14
14 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. No-Step (No Dose Escalation) MariTide Tolerability was Improved at Initiation With One-Step Dose Escalation One-Step Dose Escalation 100 90 80 70 60 50 40 30 20 10 0 Vomiting Incidence rate (%)1 2 4 8 12 16 20 24 28 32 36 40 44 48 Time since first dose of IP (weeks) 100 90 80 70 60 50 40 30 20 10 0 Vomiting Incidence rate (%)1 2 4 8 12 16 20 24 28 32 36 40 44 48 Time since first dose of IP (weeks) 420 mg Q4W (4W-Dose Escalation) 420 mg Q4W (12W-Dose Escalation) 52 52 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 70 mg 70 mg 140 mg 280 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 70 mg Mild Moderate Severe 100 90 80 70 60 50 40 30 20 10 0 Vomiting Incidence rate (%)1 2 4 8 12 16 20 24 28 32 36 40 44 48 Time since first dose of IP (weeks) 100 90 80 70 60 50 40 30 20 10 0 Vomiting Incidence rate (%)1 2 4 8 12 16 20 24 28 32 36 40 44 48 Time since first dose of IP (weeks) 420 mg Q4W 420 mg Q8W 52 52 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg 420 mg The incidence graph captures the proportion of subjects who have an AE start within the period captured. For example, during week 1, this is the proportion of subjects with a new AE reported during days 1-7. IP = investigational product; mg = milligrams; Q4W = every 4 weeks; Q8W = every 8 weeks; W= week; AE = adverse event.
Page 15
15 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. DAY 1 RANDOMIZATION 1:1:1 N= 121 DAY 15 DAY 29 7 0 m g 70 mg 70 mg 70 mg Continued Follow-up END OF STUDY 21 mg 35 mg 70 mg 350 mg 350 mg 350 mg Phase 1 Center Phase 1 Center Phase 1 Center Primary Analysis DAY 43 DAY 99 GROUP 1 2 3 Participants were administered MariTide on Day 1, Day 15, and Day 29 Two-Step Dose Escalation was Evaluated Through a Phase 1 Low Dose Initiation Study A Randomized, Double-Blind, Multiple-Dose Study. Double-blind administration using placebo double-dummy. mg = milligrams.
Page 16
16 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. Two-Step Dose Escalation Improved Incident GI Adverse Events and Reinforced That Events Were Short Lived Individual Participants (one row per individual) Days Group 1: two-step dose escalation 21/70/350 mg Group 2: two-step dose escalation 35/70/350 mg Group 3: one-step dose escalation 70/70/350 mg Participants were administered MariTide on Day 1, Day 15, and Day 29. GI adverse events are short lived and predominantly clustered with the initial doses of MariTide GI = gastrointestinal; mg = milligrams. Mild Moderate SevereNo event
Page 17
17 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. Meaningful Improvements in Tolerability Observed With Each Additional Dose Escalation Step 0 10 20 30 40 50 60 70 80 90 100 420 mg 280 mg 140 mg 70/70/ 350 mg 70/140/ 280/420 mg 70/70/ 420 mg 35/70/ 350 mg 21/70/ 350 mg No-Step One-Step Dose Escalation Two-Step Dose Escalation No-step to target dose Two steps to target dose with lower starting dose One step to target dose with 70mg starting dose Vomiting incidence % Use three-step dose escalation to further improve tolerability in Phase 3 mg = milligrams.
Page 18
18 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. -5.5 -7.0 -6.2 -10 -7.5 -5 -2.5 0 0 5 10 15 20 25 30 35 40 Mean baseline weight = 100.6 kg Dose Escalation in the MariTide Phase 1 Low Dose Initiation Study Delivered Meaningful Weight Loss Group 1: 21/70/350 mg, n=41 Group 2: 35/70/350 mg, n=40 Group 3: 70/70/350 mg, n=40 % Change from baseline in body weight Day MariTide administration: Participants were administered MariTide on Day 1, Day 15, and Day 29. kg = kilograms; mg = milligrams.
Page 19
19 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. Three-Step Dose Escalation Will be Used to Further Improve MariTide’s Tolerability Profile in Phase 3 Dose Escalation No-Step One-Step Two-Step Three-Step Study Phase 2 Phase 2 Phase 1 LDI Phase 3 Duration – 2-4 weeks 4 weeks 8 weeks Nausea Vomiting High Lower Even Lower Expect Further Improvement in Phase 3 Dosing Scheme No-step to target dose 70 mg → Target dose 35 mg → 70 mg → Target 21 mg → 70 mg → Target 21mg → 35 mg → 70mg → Target LDI = Low Dose Initiation Study; mg = milligrams.
Page 20
20 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. MariTide Phase 3 Chronic Weight Management Study Designs WITH and WITHOUT Type 2 Diabetes W 72 Treatment period Day 1 W2 W4 W8 Target Dose: 350 mg MariTide monthly Target Dose: 210 mg MariTide monthly 35 mg21 mg Target dose: 140 mg MariTide monthly Placebo monthly 8 week three-step dose escalation 35 mg21 mg 35 mg21 mg 70 mg 70 mg 70 mg Placebo Three target doses Placebo Placebo • 72-week duration to enable further long-term efficacy and durability evaluation • Three target doses to accommodate a range of participant needs • Optimized three-step dose escalation informed by pharmacokinetic analysis and GI adverse event learnings The 72-week treatment period includes a dose escalation period of 8 weeks and a 64-week target dose period. Adjunct to reduced-calorie diet and increased physical activity. Two studies, one in adult participants without Type 2 diabetes mellitus who have obesity or are overweight and the second in adult participants with Type 2 diabetes mellitus who have obesity or are overweight. GI = gastrointestinal; mg = milligrams; W = week.
Page 21
21 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. MariTide Data Generation Atherosclerotic Cardiovascular Disease Outcomes Obstructive sleep apnea Heart failure Additional Phase 3 study initiations Part 2 of the Phase 2 study Phase 2 Type 2 diabetes study Studies in Progress Phase 3 chronic weight management study in patients WITHOUT Type 2 diabetes Phase 3 chronic weight management study in patients WITH Type 2 diabetes
Page 22
22 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. Key Takeaways HbA1c = hemoglobin A1c; GLP-1 = glucagon-like peptide 1. • First obesity treatment with monthly or less frequent dosing • Strong efficacy with up to ~20% weight loss without a plateau at 52 weeks • Meaningful improvements in cardiometabolic parameters including HbA1c, systolic blood pressure, and high-sensitivity C-reactive protein • Tolerability consistent with the GLP -1 class for gastrointestinal adverse events and overall • Dose escalation significantly improves tolerability without compromising weight loss efficacy • Phase 3 MARITIME chronic weight management studies underway with further optimized three- step dose escalation for additional tolerability improvements • MariTide’s simple and convenient dosing can potentially improve adherence and long -term weight control, providing the opportunity to optimize health outcomes for people living with obesity and obesity related conditions including Type 2 diabetes
Page 23
QUESTIONS?
Page 24
24 Observed Pharmacokinetics MariTide plasma exposure generally increased with increasing Day 1 dose (21, 35, or 70 mg SC) Day 1 (MariTide 21, 35, or 70 mg SC) Group tmax (day) Cmax (µg/mL) AUC0-14 (day × µg/mL) Group 1: 21/70/350 mg N = 41 9.0 (2.0-14.0) 1.08 (52.8%) 11.3 (59.0%) Group 2: 35/70/350 mg N = 40 7.0 (3.0-14.1) 1.95 (47.9%) 20.6 (50.7%) Group 3:70/70/350 mg N = 40 7.0 (3.0-14.1) 3.24 (40.1%) 34.7 (41.4%)* Day 15 (MariTide 70 mg SC) Group tmax (day) Cmax (µg/mL) AUC0-14 (day × µg/mL) Group 1: 21/70/350 mg N = 41 7.0 (2.0-14.1) 4.69 (46.5%) 54.0 (45.5%)† Group 2: 35/70/350 mg N = 40 7.0 (3.0-14.1) 5.66 (38.9%) 64.9 (39.1%) Group 3:70/70/350 mg N = 40 5.0 (3.0-14.0)‡ 5.82 (42.8%)‡ 67.2 (41.3%)‡ Day 29 (MariTide 350 mg SC) Group tmax (day) Cmax (µg/mL) AUC0-14 (day × µg/mL) Group 1: 21/70/350 mg N=41 7.0 (3.0-14.0)* 23.2 (50.1%)* 267 (47.4%)* Group 2: 35/70/350 mg N=40 7.0 (3.0-15.2)† 24.2 (32.2%)† 281 (32.5%)† Group 3:70/70/350 mg N=40 7.0 (2.0-9.1)‡ 21.1 (38.1%)‡ 237 (37.9%)‡ Group 1: 21/70/350 mg Group 2: 35/70/350 mg Group 3: 70/70/350 mg 100.0 0.1 1.0 10.0 Mean MariTide Plasma Concentration (µg/mL) 1 8 15 22 29 36 Time Post-dose (days) * n=38, †n=39, ‡n=37 Data are presented as geometric mean (coefficient of variation, CV%), except for tmax, which is presented as median (range).’
Page 25
25 Provided June 23, 2025, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. About Phase 2 Efficacy Estimand and Treatment Policy Estimand (Intent-to-Treat Analysis) • The efficacy estimand represents the efficacy as if treated participants had adhered to MariTide for the entire 52-week study period. The efficacy estimand includes endpoint data so long as study drug is taken. Where endpoint data is missing with early discontinuation, the endpoint results for the patient are estimated using individual patient response and predicted performance after drug discontinuation. • The treatment policy estimand, i.e., intent-to-treat analysis, represents the efficacy of treated participants regardless of adherence to MariTide for the entire 52 -week study period and conforms to regulatory guidance for clinical trials. The treatment policy estimand includes all endpoint data, irrespective of whether study drug is taken or not. Where endpoint data is missing with early discontinuation, this approach assumes the endpoint for the study patient approximates that of placebo. • The difference between the results generated by the efficacy estimand and the treatment policy estimand was driven by early discontinuations and a conservatively defined treatment estimand used in the Phase 2 study.